 | • レポートコード：D0SP201105 • 出版社/出版日：Transparency Market Research / 2020年10月30日 • レポート形態：英文、PDF、204ページ • 納品方法：Eメール • 産業分類：医薬品 |
| Single User | ￥857,660 (USD5,795) | ▷ お問い合わせ |
| Multi User | ￥1,301,660 (USD8,795) | ▷ お問い合わせ |
| Corporate License | ￥1,745,660 (USD11,795) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本市場調査レポートでは、呼吸器系抗ウイルス治療の世界市場について調査・分析し、序論、仮定・調査手法、エグゼクティブサマリー、市場概要、市場動向、医薬品クラス別（ヌクレオシド類似体、ノイラミニダーゼ阻害剤、イオンチャネル遮断薬、融合タンパク質阻害剤）分析、疾患種類別（インフルエンザ、細気管支炎、肺炎、上気道感染症（URTI）、その他）分析、流通チャネル別（病院薬局、小売薬局、オンライン薬局）分析、最終用途別（商業用、非商業用）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ）分析、競争状況などの項目を掲載しています。 ・序論 ・仮定/調査手法 ・エグゼクティブサマリー ・市場概要 ・市場動向 ・呼吸器系抗ウイルス治療の世界市場規模：医薬品クラス別（ヌクレオシド類似体、ノイラミニダーゼ阻害剤、イオンチャネル遮断薬、融合タンパク質阻害剤） ・呼吸器系抗ウイルス治療の世界市場規模：疾患種類別（インフルエンザ、細気管支炎、肺炎、上気道感染症（URTI）、その他） ・呼吸器系抗ウイルス治療の世界市場規模：流通チャネル別（病院薬局、小売薬局、オンライン薬局） ・呼吸器系抗ウイルス治療の世界市場規模：最終用途別（商業用、非商業用） ・呼吸器系抗ウイルス治療の世界市場規模：地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ） ・競争状況 |
Respiratory Antiviral Treatment Market – Scope of the Report
TMR’s report on the global respiratory antiviral treatment market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators for the market during the forecast period from 2020 to 2030. The report provides revenue of the global respiratory antiviral treatment market for the period 2018–2030, considering 2019 as the base year and 2030 as the forecast year. The report also provides the compound annual growth rate (CAGR) of the global respiratory antiviral treatment market from 2020 to 2030.
The report is prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the respiratory antiviral treatment market.
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the respiratory antiviral treatment market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report sheds light on the changing competitive dynamics in the global respiratory antiviral treatment market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global respiratory antiviral treatment market.
The report delves into the competition landscape of the global respiratory antiviral treatment market. Key players operating in the global respiratory antiviral treatment market are identified and each one of these is profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global respiratory antiviral treatment market profiled in this report.
Key Questions Answered in Respiratory Antiviral Treatment Market Report
What is the sales/revenue generated by respiratory antiviral treatment across all regions during the forecast period?
What are the opportunities in the global respiratory antiviral treatment market?
What are the major drivers, restraints, opportunities, and threats in the market?
Which regional market is set to expand at the fastest CAGR during the forecast period?
Which drug class segment is expected to generate the highest revenue globally in 2030? Which segment is projected to expand at the highest CAGR during the forecast period?
What are the market positions of different companies operating in the global market?
Respiratory Antiviral Treatment Market – Research Objectives and Research Approach
The comprehensive report on the global respiratory antiviral treatment market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.
For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller sections. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.
The report analyzes the global respiratory antiviral treatment market in terms of drug class, disease type, distribution channel, and region. Key segments under each criteria are studied at length, and the market share for each of these at the end of 2030 has also been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global respiratory antiviral treatment market.
レポート目次1. Preface
1.1. Report Scope and Market Segmentation
1.2. Research Highlights
2. Assumptions and Research Methodology
2.1. Assumptions and Acronyms Used
2.2. Research Methodology
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Key Industry Developments
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunity
4.4. Global Respiratory Antiviral Treatment Market Forecast
4.5. Global Respiratory Antiviral Treatment Market Outlook
5. Market Outlook
5.1. Pipeline Analysis
5.2. Disease Prevalence Rate Globally with Key Countries
5.3. COVID-19 Impact Analysis
6. Global Respiratory Antiviral Treatment Market Analysis, by Drug Class
6.1. Introduction
6.2. Global Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Drug Class
6.3. Global Respiratory Antiviral Treatment Market Forecast, by Drug Class
6.3.1. Nucleoside Analogs
6.3.1.1. Ribavirin
6.3.1.2. Aciclovir
6.3.1.3. Others
6.3.2. Neuraminidase Inhibitors
6.3.2.1. Oseltamivir
6.3.2.2. Zanamivir
6.3.2.3. Others
6.3.3. Ion Channel Blockers
6.3.4. Fusion Protein Inhibitors
6.4. Global Respiratory Antiviral Treatment Market Analysis, by Drug Class
7. Global Respiratory Antiviral Treatment Market Analysis, by Disease Type
7.1. Introduction
7.2. Global Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Disease Type
7.3. Global Respiratory Antiviral Treatment Market Forecast, by Disease Type
7.3.1. Influenza
7.3.2. Bronchiolitis
7.3.3. Pneumonia
7.3.4. Upper Respiratory Tract Infections (URTIs)
7.3.5. Others (measles, etc.)
7.4. Global Respiratory Antiviral Treatment Market Analysis, by Disease Type
8. Global Respiratory Antiviral Treatment Market Analysis, by Distribution Channel
8.1. Introduction
8.2. Global Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Distribution Channel
8.3. Global Respiratory Antiviral Treatment Market Forecast, by Distribution Channel
8.3.1. Hospital Pharmacies
8.3.2. Retail Pharmacies
8.3.3. Online Pharmacies
8.4. Global Respiratory Antiviral Treatment Market Analysis, by Route of Administration
9. Global Respiratory Antiviral Treatment Market Analysis, by Region
9.1. Global Respiratory Antiviral Treatment Market Scenario, by Region/Country
9.2. Global Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Region
9.3. Global Respiratory Antiviral Treatment Market Forecast, by Region
9.3.1. North America
9.3.2. Europe
9.3.3. Asia Pacific
9.3.4. Latin America
9.3.5. Middle East & Africa
10. North America Respiratory Antiviral Treatment Market Analysis
10.1. North America Respiratory Antiviral Treatment Market Overview
10.2. North America Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Country
10.3. North America Respiratory Antiviral Treatment Market Forecast, by Country
10.3.1. U.S.
10.3.2. Canada
10.4. North America Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Drug Class
10.5. North America Respiratory Antiviral Treatment Market Forecast, by Drug Class
10.5.1. Nucleoside Analogs
10.5.1.1. Ribavirin
10.5.1.2. Aciclovir
10.5.1.3. Others
10.5.2. Neuraminidase Inhibitors
10.5.2.1. Oseltamivir
10.5.2.2. Zanamivir
10.5.2.3. Others
10.5.3. Ion Channel Blockers
10.5.4. Fusion Protein Inhibitors
10.6. North America Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Disease Type
10.7. North America Respiratory Antiviral Treatment Market Forecast, by Disease Type
10.7.1. Influenza
10.7.2. Bronchiolitis
10.7.3. Pneumonia
10.7.4. Upper Respiratory Tract Infections (URTIs)
10.7.5. Others (measles, etc.)
10.8. North America Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Distribution Channel
10.9. North America Respiratory Antiviral Treatment Market Forecast, by Distribution Channel
10.9.1. Hospital Pharmacies
10.9.2. Retail Pharmacies
10.9.3. Online Pharmacies
11. Europe Respiratory Antiviral Treatment Market Analysis
11.1. Europe Respiratory Antiviral Treatment Market Overview
11.2. Europe Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Country/Sub-region
11.3. Europe Respiratory Antiviral Treatment Market Forecast, by Country/Sub-region
11.3.1. Germany
11.3.2. France
11.3.3. U.K.
11.3.4. Italy
11.3.5. Spain
11.3.6. Rest of Europe
11.4. Europe Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Drug Class
11.5. Europe Respiratory Antiviral Treatment Market Forecast, by Drug Class
11.5.1. Nucleoside Analogs
11.5.1.1. Ribavirin
11.5.1.2. Aciclovir
11.5.1.3. Others
11.5.2. Neuraminidase Inhibitors
11.5.2.1. Oseltamivir
11.5.2.2. Zanamivir
11.5.2.3. Others
11.5.3. Ion Channel Blockers
11.5.4. Fusion Protein Inhibitors
11.6. Europe Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Disease Type
11.7. Europe Respiratory Antiviral Treatment Market Forecast, by Disease Type
11.7.1. Influenza
11.7.2. Bronchiolitis
11.7.3. Pneumonia
11.7.4. Upper Respiratory Tract Infections (URTIs)
11.7.5. Others (measles, etc.)
11.8. Europe Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Distribution Channel
11.9. Europe Respiratory Antiviral Treatment Market Forecast, by Distribution Channel
11.9.1. Hospital Pharmacies
11.9.2. Retail Pharmacies
11.9.3. Online Pharmacies
12. Asia Pacific Respiratory Antiviral Treatment Market Analysis
12.1. Asia Pacific Respiratory Antiviral Treatment Market Overview
12.2. Asia Pacific Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Country/Sub-region
12.3. Asia Pacific Respiratory Antiviral Treatment Market Forecast, by Country/Sub-region
12.3.1. Japan
12.3.2. China
12.3.3. India
12.3.4. Australia & New Zealand
12.3.5. Rest of Asia Pacific
12.4. Asia Pacific Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Drug Class
12.5. Asia Pacific Respiratory Antiviral Treatment Market Forecast, by Drug Class
12.5.1. Nucleoside Analogs
12.5.1.1. Ribavirin
12.5.1.2. Aciclovir
12.5.1.3. Others
12.5.2. Neuraminidase Inhibitors
12.5.2.1. Oseltamivir
12.5.2.2. Zanamivir
12.5.2.3. Others
12.5.3. Ion Channel Blockers
12.5.4. Fusion Protein Inhibitors
12.6. Asia Pacific Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Disease Type
12.7. Asia Pacific Respiratory Antiviral Treatment Market Forecast, by Disease Type
12.7.1. Influenza
12.7.2. Bronchiolitis
12.7.3. Pneumonia
12.7.4. Upper Respiratory Tract Infections (URTIs)
12.7.5. Others (measles, etc.)
12.8. Asia Pacific Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Distribution Channel
12.9. Asia Pacific Respiratory Antiviral Treatment Market Forecast, by Distribution Channel
12.9.1. Hospital Pharmacies
12.9.2. Retail Pharmacies
12.9.3. Online Pharmacies
13. Latin America Respiratory Antiviral Treatment Market Analysis
13.1. Latin America Respiratory Antiviral Treatment Market Overview
13.2. Latin America Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Country/Sub-region
13.3. Latin America Respiratory Antiviral Treatment Market Forecast, by Country/Sub-region
13.3.1. Brazil
13.3.2. Mexico
13.3.3. Rest of Latin America
13.4. Latin America Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Drug Class
13.5. Latin America Respiratory Antiviral Treatment Market Forecast, by Drug Class
13.5.1. Nucleoside Analogs
13.5.1.1. Ribavirin
13.5.1.2. Aciclovir
13.5.1.3. Others
13.5.2. Neuraminidase Inhibitors
13.5.2.1. Oseltamivir
13.5.2.2. Zanamivir
13.5.2.3. Others
13.5.3. Ion Channel Blockers
13.5.4. Fusion Protein Inhibitors
13.6. Latin America Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Disease Type
13.7. Latin America Respiratory Antiviral Treatment Market Forecast, by Disease Type
13.7.1. Influenza
13.7.2. Bronchiolitis
13.7.3. Pneumonia
13.7.4. Upper Respiratory Tract Infections (URTIs)
13.7.5. Others (measles, etc.)
13.8. Latin America Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Distribution Channel
13.9. Latin America Respiratory Antiviral Treatment Market Forecast, by Distribution Channel
13.9.1. Hospital Pharmacies
13.9.2. Retail Pharmacies
13.9.3. Online Pharmacies
14. Middle East & Africa Respiratory Antiviral Treatment Market Analysis
14.1. Middle East & Africa Respiratory Antiviral Treatment Market Overview
14.2. Middle East & Africa Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Country/Sub-region
14.3. Middle East & Africa Respiratory Antiviral Treatment Market Forecast, by Country/Sub-region
14.3.1. GCC Countries
14.3.2. South Africa
14.3.3. Rest of Middle East & Africa
14.4. Middle East & Africa Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Drug Class
14.5. Middle East & Africa Respiratory Antiviral Treatment Market Forecast, by Drug Class
14.5.1. Nucleoside Analogs
14.5.1.1. Ribavirin
14.5.1.2. Aciclovir
14.5.1.3. Others
14.5.2. Neuraminidase Inhibitors
14.5.2.1. Oseltamivir
14.5.2.2. Zanamivir
14.5.2.3. Others
14.5.3. Ion Channel Blockers
14.5.4. Fusion Protein Inhibitors
14.6. Middle East & Africa Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Disease Type
14.7. Middle East & Africa Respiratory Antiviral Treatment Market Forecast, by Disease Type
14.7.1. Influenza
14.7.2. Bronchiolitis
14.7.3. Pneumonia
14.7.4. Upper Respiratory Tract Infections (URTIs)
14.7.5. Others (measles, etc.)
14.8. Middle East & Africa Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Distribution Channel
14.9. Middle East & Africa Respiratory Antiviral Treatment Market Forecast, by Distribution Channel
14.9.1. Hospital Pharmacies
14.9.2. Retail Pharmacies
14.9.3. Online Pharmacies
15. Competition Landscape
15.1. Competition Matrix
15.2. Company Profiles
15.2.1. F. Hoffmann-La Roche Ltd.
15.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.1.2. Financial Overview
15.2.1.3. Product Portfolio
15.2.1.4. SWOT Analysis
15.2.1.5. Strategic Overview
15.2.2. Novartis AG
15.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.2.2. Financial Overview
15.2.2.3. Product Portfolio
15.2.2.4. SWOT Analysis
15.2.2.5. Strategic Overview
15.2.3. Takeda Pharmaceutical Company Limited
15.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.3.2. Financial Overview
15.2.3.3. Product Portfolio
15.2.3.4. SWOT Analysis
15.2.3.5. Strategic Overview
15.2.4. Pfizer, Inc.
15.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.4.2. Product Portfolio
15.2.4.3. SWOT Analysis
15.2.4.4. Strategic Overview
15.2.5. Teva Pharmaceutical Industries Ltd.
15.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.5.2. Financial Overview
15.2.5.3. Product Portfolio
15.2.5.4. SWOT Analysis
15.2.5.5. Strategic Overview
15.2.6. Sun Pharmaceutical Industries Ltd.
15.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.6.2. Financial Overview
15.2.6.3. Product Portfolio
15.2.6.4. SWOT Analysis
15.2.6.5. Strategic Overview
15.2.7. GlaxoSmithKline plc
15.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.7.2. Financial Overview
15.2.7.3. Product Portfolio
15.2.7.4. SWOT Analysis
15.2.7.5. Strategic Overview
15.2.8. Mylan, Inc.
15.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.8.2. Financial Overview
15.2.8.3. Product Portfolio
15.2.8.4. SWOT Analysis
15.2.8.5. Strategic Overview
15.2.9. Merck & Co., Inc.
15.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.9.2. Financial Overview
15.2.9.3. Product Portfolio
15.2.9.4. SWOT Analysis
15.2.9.5. Strategic Overview
15.2.10. AstraZeneca plc.
15.2.10.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.10.2. Financial Overview
15.2.10.3. Product Portfolio
15.2.10.4. SWOT Analysis
15.2.10.5. Strategic Overview
List of TablesTable 01: Global Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030
Table 02: Global Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Nucleoside Analogs, 2018–2030
Table 03: Global Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Neuraminidase Inhibitors, 2018–2030
Table 04: Global Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Disease Type, 2018–2030
Table 05: Global Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030
Table 06: Global Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Region, 2018–2030
Table 07: North America Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Country, 2018–2030
Table 08: North America Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030
Table 09: North America Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Nucleoside Analogs, 2018–2030
Table 10: North America Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Neuraminidase Inhibitors, 2018–2030
Table 11: North America Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Disease Type, 2018–2030
Table 12: North America Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030
Table 13: Europe Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030
Table 14: Europe Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030
Table 15: Europe Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Nucleoside Analogs, 2018–2030
Table 16: Europe Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Neuraminidase Inhibitors, 2018–2030
Table 17: Europe Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Disease Type, 2018–2030
Table 18: Europe Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030
Table 19: Asia Pacific Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030
Table 20: Asia Pacific Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030
Table 21: Asia Pacific Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Nucleoside Analogs, 2018–2030
Table 22: Asia Pacific Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Neuraminidase Inhibitors, 2018–2030
Table 23: Asia Pacific Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Disease Type, 2018–2030
Table 24: Asia Pacific Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030
Table 25: Latin America Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030
Table 26: Latin America Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030
Table 27: Latin America Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Nucleoside Analogs, 2018–2030
Table 28: Latin America Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Neuraminidase Inhibitors, 2018–2030
Table 29: Latin America Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Disease Type, 2018–2030
Table 30: Latin America Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030
Table 31: Middle East & Africa Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030
Table 32: Middle East & Africa Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030
Table 33: Middle East & Africa Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Nucleoside Analogs, 2018–2030
Table 34: Middle East & Africa Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Neuraminidase Inhibitors, 2018–2030
Table 35: Middle East & Africa Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Disease Type, 2018–2030
Table 36: Middle East & Africa Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030